A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma that has Spread to the Brain

I3Y-MC-JPBO -

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Breast Cancer, Lung Cancer, Melanoma
What the trial is testing?
Abemaciclib
Could I receive a Placebo?
No
Enrollment Goal
162
Trial Dates
Apr 20, 2015 - Nov 8, 2019
How long will I be in the trial?
Your participation could last approximately 5 months depending on how you and your tumor respond.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.